Monitoring non-invasive Streptococcus pneumoniae infections in Belgium
A 20-months Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium to Evaluate National Vaccination Strategy
Sciensano · NCT04447521
This study is tracking infections caused by Streptococcus pneumoniae in Belgium to see how common different types are and how resistant they are to antibiotics, using samples from patients with pneumonia, ear infections, or sinusitis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3600 (estimated) |
| Sex | All |
| Sponsor | Sciensano (other gov) |
| Locations | 1 site (Brussels) |
| Trial ID | NCT04447521 on ClinicalTrials.gov |
What this trial studies
This observational study aims to monitor non-invasive infections caused by Streptococcus pneumoniae in Belgium from September 2020 to May 2025. Twelve peripheral hospitals will collect and send the first 15 unduplicated clinical samples of S. pneumoniae from patients diagnosed with pneumonia, otitis media, or sinusitis each month. The study will analyze the serotype distribution and antibiotic resistance profiles of these isolates, with whole genome sequencing performed on a subset. An additional 13 centers joined the study in May 2021 to enhance data collection.
Who should consider this trial
Good fit: Ideal candidates include patients living in Belgium diagnosed with pneumonia, sinusitis, or otitis media from whom non-invasive S. pneumoniae samples are collected.
Not a fit: Patients from whom S. pneumoniae is isolated from blood or other sterile specimens will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of national vaccination programs against S. pneumoniae.
How similar studies have performed: Other studies have successfully monitored bacterial infections and their serotypes, making this approach well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients living in Belgium at the time of the study, * from whom unduplicated S. pneumoniae isolates were collected in routine practices, * from non-invasive upper (e.g.: pus/fluid from nasal sinus or from otitis media fluid) or lower respiratory tract (e.g. sputum bronchial or endotracheal aspirate, bronchoalveolar fluid (BAL),...) clinical samples, * from patients diagnosed with pneumonia, sinusitis and otitis. Exclusion Criteria: • Patients for whom S. pneumoniae was simultaneously isolated from blood or another usually sterile specimen
Where this trial is running
Brussels
- Sciensano — Brussels, Belgium (RECRUITING)
Study contacts
- Principal investigator: Pieter-Jan Ceyssens, PhD — Sciensano
- Study coordinator: Pieter-Jan Ceyssens, PhD
- Email: pieter-jan.ceyssens@sciensano.be
- Phone: 02 373 31 19
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pneumonia, Otitis Media, Sinusitis Bacterial